Description
Description: Bdron, also known by its international brand name Zytiga, is a pharmaceutical product manufactured by BDR Pharmaceuticals Int’l Pvt Ltd. It contains Abiraterone Acetate as its active substance and is primarily used in the treatment of prostate cancer. Bdron is available in tablet form, with each tablet containing 250 mg of Abiraterone Acetate.
Active Substance: Abiraterone Acetate is an androgen biosynthesis inhibitor that works by selectively inhibiting the enzyme CYP17 (17α-hydroxylase/C17,20-lyase). This enzyme is involved in the biosynthesis of androgens (male hormones) in the adrenal glands and the prostate tumor tissue. By inhibiting CYP17, Abiraterone reduces the production of androgens, including testosterone and dihydrotestosterone (DHT), which are known to stimulate prostate cancer growth.
Manufacturer: Bdron is manufactured by BDR Pharmaceuticals Int’l Pvt Ltd, a reputable pharmaceutical company known for its commitment to producing high-quality medications. BDR Pharmaceuticals adheres to stringent manufacturing standards to ensure the safety, efficacy, and consistency of its products.
Strength and Formulation: Each tablet of Bdron contains 250 mg of Abiraterone Acetate as the active ingredient. The tablets are formulated for oral administration, making them convenient for patients to take as directed by their healthcare provider.
Packaging: Bdron is typically available in a pack containing 120 tablets. This packaging provides an ample supply of medication for the prescribed treatment duration, ensuring continuity of therapy and convenience for patients.
Indications: Bdron (Abiraterone) is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men. It is used in combination with prednisone or prednisolone, as it helps to lower the production of androgens, which can slow down the progression of prostate cancer.
Usage and Dosage: The recommended dosage of Bdron (Abiraterone) may vary depending on factors such as the patient’s medical condition, treatment response, and tolerability. Typically, the usual dose is 1000 mg (four tablets) once daily, taken orally on an empty stomach, at least one hour before or two hours after eating. The tablets should be swallowed whole with water and should not be crushed, chewed, or divided.
Storage Conditions: Bdron tablets should be stored according to the manufacturer’s instructions, typically in a cool, dry place, away from direct sunlight, and at room temperature. They should be kept out of reach of children and pets to prevent accidental ingestion. Proper storage helps maintain the stability and efficacy of the medication.
Patients should consult their healthcare provider for personalized information regarding the use of Bdron, including dosage adjustments, potential side effects, and monitoring during treatment. Regular follow-up appointments are essential to evaluate treatment response and manage any adverse reactions.
Reviews
There are no reviews yet.